• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis.

作者信息

Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K, Sasazuki T

机构信息

Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

出版信息

Cancer Res. 1992 May 15;52(10):2903-6.

PMID:1581907
Abstract

Adenocarcinoma of the lung obtained at surgical resection was examined for mutation at codons 12, 13, and 61 of the oncogenes K-ras, H-ras, and N-ras, using polymerase chain reaction and oligonucleotide hybridization techniques. The mutation was detected in 18 of the 115 cases (15.7%), and 15 of 18 were at codon 12, 2 were at codon 13 of K-ras, and 1 was at codon 61 of N-ras. G to T transversions were most common. The ras gene mutations were more frequent in the male patients (P = 0.0048). No significant differences were found to be related to stage of the disease or tumor-nodes-metastases classification between positive and negative groups of the ras gene mutations. A history of tobacco use was not always a factor contributing to mutation. Of the completely resected group without lymph node metastasis, the 5-year survival rate in the ras-positive group was 53.3%, which was significantly poorer than the 83.6% survival rate in the ras-negative group (P less than 0.05). Our findings suggest that ras gene mutations may be prognostic, especially in the early stage adenocarcinoma of the lung.

摘要

相似文献

1
ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis.
Cancer Res. 1992 May 15;52(10):2903-6.
2
Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.吸烟与不吸烟女性肺癌中p53和K-ras基因突变的比较。
Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 1):297-302.
3
[Detection of K-ras oncogene activation in human lung cancer and its possible clinical application].[人肺癌中K-ras癌基因激活的检测及其可能的临床应用]
Zhonghua Jie He He Hu Xi Za Zhi. 1995 Oct;18(5):282-4, 317.
4
K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.K-ras癌基因激活作为肺腺癌的一种预后标志物
N Engl J Med. 1990 Aug 30;323(9):561-5. doi: 10.1056/NEJM199008303230902.
5
Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients.K-ras基因突变对手术切除的非小细胞肺癌患者的预后影响
Oncogene. 1993 Sep;8(9):2407-12.
6
C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.C-erbB-2表达和第12密码子K-ras突变均预示肺腺癌患者生存期缩短。
J Clin Invest. 1994 Feb;93(2):516-20. doi: 10.1172/JCI117001.
7
K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.人类胰腺腺癌中的K-ras癌基因激活。使用富集突变体聚合酶链反应分析和等位基因特异性寡核苷酸杂交相结合的方法对82例癌进行的研究。
Am J Pathol. 1993 Aug;143(2):545-54.
8
Detection of occult metastases in sentinel lymph nodes from colon cancer patients by K-ras mutation peptide nucleic acid clamp PCR.K-ras 突变肽核酸夹 PCR 检测结肠癌患者前哨淋巴结隐匿性转移。
Ann Surg. 2010 Jun;251(6):1087-91. doi: 10.1097/SLA.0b013e3181dae1bc.
9
Adenocarcinoma of the pancreas: detection of occult metastases in regional lymph nodes by a polymerase chain reaction-based assay.胰腺腺癌:通过基于聚合酶链反应的检测方法检测区域淋巴结中的隐匿性转移灶。
Cancer. 1998 Oct 1;83(7):1328-34.
10
Detection of K-ras mutations in lung carcinomas: relationship to prognosis.肺癌中K-ras突变的检测:与预后的关系。
Clin Cancer Res. 1996 Feb;2(2):411-8.

引用本文的文献

1
Reassessing the roles of oxidative DNA base lesion 8-oxoGua and repair enzyme OGG1 in tumorigenesis.重新评估氧化性DNA碱基损伤8-氧代鸟嘌呤(8-oxoGua)和修复酶OGG1在肿瘤发生中的作用。
J Biomed Sci. 2025 Jan 1;32(1):1. doi: 10.1186/s12929-024-01093-8.
2
Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.手术切除的表皮生长因子受体和 K-ras 突变的病理 I 期肺腺癌的临床病理和预后特征。
Thorac Cancer. 2017 May;8(3):229-237. doi: 10.1111/1759-7714.12428. Epub 2017 Mar 21.
3
Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors.
厚朴酚通过靶向表皮生长因子受体(EGFR)及其下游效应分子来抑制肺癌发生。
Oncotarget. 2016 Sep 6;7(36):57752-57769. doi: 10.18632/oncotarget.10759.
4
Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.切除的病理I期肺腺癌中EGFR、K-ras、EML4-ALK和BRAF基因的突变
Surg Today. 2016 Sep;46(9):1091-8. doi: 10.1007/s00595-015-1295-z. Epub 2015 Dec 28.
5
Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer.肺癌中具有预测和预后相关性的分子标志物
Lung Cancer Int. 2012;2012:729532. doi: 10.1155/2012/729532. Epub 2012 Sep 19.
6
Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance.切除的 I 期肺腺癌中 EGFR 和 K-ras 基因突变及其临床意义。
Surg Today. 2014 Mar;44(3):478-86. doi: 10.1007/s00595-013-0589-2. Epub 2013 Apr 23.
7
TPL2 kinase is a suppressor of lung carcinogenesis.TPL2 激酶是肺癌发生的抑制因子。
Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):E1470-9. doi: 10.1073/pnas.1215938110. Epub 2013 Mar 26.
8
A rare point mutation in the Ras oncogene in hepatocellular carcinoma.肝癌中 Ras 癌基因的罕见点突变。
Surg Today. 2013 Mar;43(3):289-92. doi: 10.1007/s00595-012-0462-8. Epub 2012 Dec 26.
9
Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients.EGFR通路相关分子标志物联合评估与非小细胞肺癌患者的预后
Br J Cancer. 2009 Jan 13;100(1):145-52. doi: 10.1038/sj.bjc.6604781. Epub 2008 Dec 2.
10
Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking.表皮生长因子受体(EGFR)基因酪氨酸激酶结构域内的突变特别发生在吸烟暴露量低的肺腺癌患者中。
Br J Cancer. 2006 Mar 27;94(6):896-903. doi: 10.1038/sj.bjc.6603040.